Study guide

17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

Key Takeaways Explain This Topic AI

Cell-free DNA (cfDNA / NIPT) screens maternal plasma for placental trophoblastic DNA fragments starting at 10 weeks gestation, achieving >99% sensitivity and specificity for Trisomy 21, but functions strictly as a screening tool that requires diagnostic confirmation.

A cfDNA 'no-call' result stems from low fetal fraction (<4%) secondary to elevated maternal BMI, early gestational age, or fetal aneuploidy (especially Trisomies 13/18 and triploidy), demanding detailed ultrasonography and diagnostic testing rather than blind repetition.

Second-trimester maternal serum alpha-fetoprotein (MSAFP) elevation (>2.5 MoM) flags open neural tube defects, abdominal wall defects (gastroschisis, omphalocele), multiple gestations, or dating inaccuracies, while low MSAFP is associated with Trisomy 21.

Diagnostic genetic procedures provide definitive fetal karyotype and chromosomal microarray: Chorionic Villus Sampling (CVS; 10–13 weeks) biopsies placental trophoblasts but cannot assess neural tube defects, whereas amniocentesis (15–20 weeks) analyzes amniotic fluid karyotype, microarray, and AFP/AChE.

Antepartum fetal surveillance utilizes the Non-Stress Test (reactive: ≥2 accelerations of 15 bpm for 15 sec in 20 min at ≥32 weeks), the 10-point Biophysical Profile (NST, breathing, movement, tone, amniotic fluid DVP ≥2 cm), and Umbilical Artery Doppler, where reversed end-diastolic flow signals imminent fetal demise.

Last updated: October 2026

Cell-Free DNA (cfDNA / NIPT) Screening

Cell-free DNA (cfDNA) screening analyzes circulating extracellular DNA fragments in maternal blood. Roughly 10% (range 4% to 20%) is derived from apoptotic placental syncytiotrophoblasts, representing the fetal fraction .

Performance & Clinical Role

Per ACOG guidelines, aneuploidy screening should be offered to all pregnant individuals regardless of baseline age-related risk.

Timing: Administered from 10 0/7 weeks gestation through term.

Performance: Achieves the highest sensitivity and specificity of any screening modality: Trisomy 21 (Down syndrome: >99% sensitivity and specificity) , Trisomy 18 (Edwards syndrome: ~97–98%) , and Trisomy 13 (Patau syndrome: ~90–99%) . It also evaluates fetal sex, sex chromosome aneuploidies (45,X; 47,XXY; 47,XXX; 47,XYY), and select microdeletions (e.g., 22q11.2 DiGeorge syndrome).

The "No-Call" Result: Low fetal fraction (<4%) accounts for most test failures, driven by elevated maternal BMI (hemodilution and adipose turnover), early gestational age (<10 weeks), maternal LMWH therapy, or fetal aneuploidy (Trisomies 13/18 and triploidy cause placental hypoplasia). ACOG recommends against reflexively redrawing cfDNA, as ~50% fail again; management mandates genetic counseling, detailed anatomical ultrasound, and diagnostic testing (CVS or amniocentesis) .

Important

Screening vs. Diagnostic Tool: cfDNA is strictly a screening test. Positive Predictive Value (PPV) depends heavily on maternal age. While PPV for Trisomy 21 exceeds 90% in a 40-year-old woman, it may be only 40% to 50% in a 20-year-old. Abnormal cfDNA must always be confirmed with diagnostic CVS or amniocentesis before irreversible pregnancy decisions are made.

  • Serum Screening Modalities & MSAFP Interpretation
  • First- & Second-Trimester Serum Screening

First-Trimester Combined Screen (11 0/7 to 13 6/7 Weeks): Measures fetal Nuchal Translucency (NT) via ultrasound plus maternal serum PAPP-A and beta-hCG . Down syndrome presents with thickened NT (≥3.0 mm), low PAPP-A, and high hCG.

Second-Trimester Quad Screen (15 0/7 to 22 6/7 Weeks; Optimal 16–18 Weeks): Measures Maternal Serum Alpha-Fetoprotein (MSAFP), hCG, Unconjugated Estriol (uE3), and Dimeric Inhibin A (DIA).

Screening Modality Gestational Window Analytes / Parameters Target Aneuploidies & Abnormal Patterns

First-Trimester Combined 11 0/7 to 13 6/7 weeks NT ultrasound, PAPP-A, hCG Trisomy 21: Thickened NT, low PAPP-A, elevated hCG

Second-Trimester Quad 15 0/7 to 22 6/7 weeks MSAFP, hCG, uE3, Inhibin A Trisomy 21: Low MSAFP, elevated hCG, low uE3, elevated Inhibin A

Second-Trimester Quad 15 0/7 to 22 6/7 weeks MSAFP, hCG, uE3, Inhibin A Trisomy 18: Low MSAFP, low hCG, low uE3, normal/low Inhibin A

Isolated MSAFP 15 0/7 to 20 0/7 weeks Maternal serum AFP alone Open Defects: MSAFP >2.5 MoM (ONTD, gastroschisis, omphalocele)

Clinical Significance of MSAFP

MSAFP is produced by the fetal yolk sac and liver, excreted into amniotic fluid via fetal urine, and enters maternal blood. Results are reported as Multiples of the Median (MoM) .

Elevated MSAFP (>2.5 MoM): The most common etiology is incorrect gestational dating (underestimation of age). Pathologic causes include open neural tube defects (anencephaly, spina bifida) , ventral wall defects (gastroschisis, omphalocele) , multiple gestation, and fetal demise. Initial workup requires targeted ultrasound to confirm dating, rule out twins, and inspect cranial anatomy ("lemon" and "banana" signs) and spine. If ultrasound is normal/inconclusive, amniocentesis for amniotic fluid AFP (AFAFP) and reflex acetylcholinesterase (AChE) is indicated.

Low MSAFP (<0.5 MoM): Associated with Trisomy 21, Trisomy 18, overestimation of gestational age, maternal diabetes, and fetal demise.

Diagnostic Procedures: CVS vs. Amniocentesis

Chorionic Villus Sampling (CVS; 10 0/7 to 13 6/7 Weeks): Transcervical or transabdominal biopsy of chorionic villi (placental trophoblasts) under ultrasound guidance. Provides definitive karyotype and microarray in the first trimester. Does not evaluate open neural tube defects and carries a 1% to 2% risk of Confined Placental Mosaicism (CPM). Procedural loss rate is ~0.1% to 0.2%.

Amniocentesis (15 0/7 to 20 0/7 Weeks): Transabdominal aspiration of 15 to 20 mL of amniotic fluid with a 20- to 22-gauge needle under ultrasound guidance. Diagnostic for karyotype, microarray, single-gene disorders, and AFAFP/AChE for neural tube defects. Loss rate is ~0.1% (1 in 1,000).

Rh Prophylaxis: Rh-negative, non-sensitized women undergoing either CVS or amniocentesis must receive RhoGAM (300 mcg) to prevent isoimmunization.

Antepartum Fetal Surveillance Modalities

Surveillance monitors fetal oxygenation in high-risk pregnancies (preeclampsia, pregestational diabetes, chronic hypertension, FGR, post-term ≥41 weeks, decreased movement):

1. Non-Stress Test (NST)

Reactive NST (≥32 Weeks): ≥2 accelerations of ≥15 bpm lasting ≥15 seconds in a 20-minute window ("15 by 15 rule").

Reactive NST (<32 Weeks): ≥2 accelerations of ≥10 bpm lasting ≥10 seconds in 20 minutes ("10 by 10 rule").

Non-Reactive NST: Lacks criteria over 40 minutes. Follow up with vibroacoustic stimulation (VAS) or proceed to a complete Biophysical Profile (BPP).

2. Biophysical Profile (BPP)

Combines the NST with real-time ultrasound assessing four variables over 30 minutes (each scored 0 or 2, max 10/10):

NST: Reactive = 2; Non-reactive = 0.

Fetal Breathing Movements: ≥1 continuous episode lasting ≥30 seconds = 2; <30 sec = 0.

Gross Body Movements: ≥3 discrete body/limb movements = 2; <3 movements = 0.

Fetal Tone: ≥1 episode of active extension with return to flexion = 2; slow/flaccid = 0.

Amniotic Fluid Volume (Chronic Marker): Single deepest vertical pocket (DVP) ≥2.0 cm (and ≥1 cm wide) = 2; DVP <2.0 cm (oligohydramnios) = 0. (Alternative: AFI >5.0 cm = 2).

Action by Score: 8/10 (normal fluid) or 10/10 is reassuring. 8/10 with abnormal fluid (DVP <2 cm) indicates chronic compromise; deliver if ≥37 weeks. 6/10 is equivocal; deliver if ≥37 weeks, or repeat in 12–24 hours if preterm. ≤4/10 is abnormal, indicating acute fetal asphyxia and requiring immediate delivery .

3. Modified BPP, CST & Umbilical Doppler

Modified BPP: Combines NST (acute CNS oxygenation) and DVP (chronic placental perfusion). Normal if NST is reactive and DVP ≥2 cm.

Contraction Stress Test (CST): Assesses FHR during 3 contractions in 10 minutes. Negative = no late decelerations. Positive = late decelerations after ≥50% of contractions (indicates uteroplacental insufficiency). Contraindicated in placenta previa, prior classical cesarean, or preterm labor.

Umbilical Artery Doppler: Evaluates placental vascular resistance in FGR. Progression to Absent End-Diastolic Flow (AEDF) or Reversed End-Diastolic Flow (REDF) signals severe placental obliteration and imminent demise, requiring urgent admission, betamethasone, and delivery.